Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

2026-01-27 - 08:51

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology strengthen the Group’s R&D portfolio in rare diseases. Achieving 2025 targets reflects successful transformation that began in 2015